Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
BIO Bio-Rad Laboratories
472.910+3.220+0.69%
Trading Session
02/07 13:16 ET
High
476.330
Open
466.170
Turnover
12.78M
Low
464.770
Pre Close
469.690
Volume
27.09K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Cytek Biosciences Partners With Bio-Rad To Expand Reagent Portfolios; Under Terms Include, Bio-Rad's High-Performing New Starbright Dyes Will Be Available To Cytek To Develop And Commercialize Reagent Products To Support High-Parameter Application
Delivering a boost to immuno-oncology and immunotherapy researchers, Cytek Biosciences, Inc. (NASDAQ:CTKB) today announced that it has entered into a strategic partnership with leading life science re
Yousif Capital Management LLC Sells 29 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Yousif Capital Management LLC decreased its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 1.0% in the 3rd quarter, according to its most recent Form 13F filing with the Se
Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Acquired by First Republic Investment Management Inc.
First Republic Investment Management Inc. lifted its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 8.5% in the 3rd quarter, according to its most recent Form 13F filing
Global Proteomics Market Report 2022 to 2030 - Featuring Agilent Technologies, Bio-Rad Laboratories, Bruker and Siemens Among Others - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Proteomics Market Share, Size, Trends, Industry Analysis Report, By Product Type, By Application, By Technology, By Region, Segment Forecast, 2022 - 2030" report has been
Creative Planning Has $594,000 Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)
Creative Planning raised its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 21.0% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The
Analysts' Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN), Bio-Rad Laboratories (BIO) and Edwards Lifesciences (EW)
Global Protein Purification and Isolation Market Report 2022 to 2027: Key Players Include Abcam, Agilent Technologies, Bio-Rad Laboratories, General Electric and Merck
Rockefeller Capital Management L.P. Grows Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)
Rockefeller Capital Management L.P. boosted its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 20.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC.
RBC Boosts Price Target on Bio-Rad Laboratories to $571 From $565, Maintains Outperform Rating
07:58 AM EST, 01/30/2023 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
Prudential Financial Inc. Sells 3,786 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Prudential Financial Inc. reduced its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 12.6% in the 3rd quarter, according to its most recent filing with the Securities an
Company Overview
More
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.
CEO： Mr. Norman Schwartz
Market： NYSE
Listing Date： 10/24/2008
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet